Impact of Body Composition on Dosimetry of 177Lu-PSMA Radioligand Therapy

Starting soon · Not applicable

Conditions studied: Carcinoma, Castration Resistant Prostatic Neoplasms

In brief

COCORIVO is an interventional study evaluating the impact of body composition on dosimetry of 177Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Body composition (muscle, lean, visceral fat, subcutaneous fat and total fat masses) will be automatically quantified from whole-body CT images acquired at 72-96h after 177Lu-PSMA injection using the Anthropometer3DNet software. Dosimetry will be evaluated for tumors and organs at risk (salivary glands, bone marrow, kidneys). The study also evaluates the impact of body composition on SUV quantification, the feasibility of single-timepoint dosimetry, and the evolution of body composition during treatment.

Key facts

Study ID

NCT07587814

Run by

Centre Henri Becquerel

People needed

100

Starts

2026-09-01

Expected to finish

2029-06-01

Last updated by the study team

2026-05-14

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Signed informed consent
• Male, age >= 18 years
• Histologically confirmed prostatic adenocarcinoma with multidisciplinary decision for 177Lu-PSMA treatment
• PSMA expression in tumor lesions confirmed by 68Ga-PSMA PET/CT
• Affiliated to or beneficiary of a social security scheme

You may not qualify if…

• Patient unable to understand the study or comply with study constraints (language barrier, psychological, geographic...)
• Patient under legal protection (tutelle, curatelle, sauvegarde de justice)

Where it is running

• Centre Henri Becquerel — Rouen, Normanie, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.